Background Cabazitaxel, abiraterone, and enzalutamide are survival-prolonging treatments
in men with castration-resistant prostate cancer (CRPC) progressing following docetaxel
chemotherapy. The sequential activity of these agents has not been studied and treatment
sequencing remains a key dilemma for clinicians. Objective To describe the antitumour
activity of cabazitaxel after docetaxel and next-generation endocrine agents. Design, setting,
and participants We report on a cohort of 59 men with progressing CRPC treated with …

The authors addressed sequencing treatments for castration-resistant prostate cancer (CaP)
in the postdocetaxel setting. Antitumor activity of cabazitaxel in 59 patients treated between
January 2008 and August 2013 was analyzed retrospectively. Forty-one patients had
previously received abiraterone (n= 32), sequential abiraterone and enzalutamide (n= 5), or
enzalutamide (n= 4). Antitumor activity was reported before and after novel endocrine drugs,
and it appeared less in abiraterone-and enzalutamide-naive patients (decreased median …